Arcturus Therapeutics Holdings (ARCT) Retained Earnings (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) posted Retained Earnings of -$541.6 million for Q1 2026, down 5.24% on a QoQ basis from -$514.6 million in Q4 2025, and down 17.0% year-over-year from -$652.4 million in Q1 2025.
Arcturus Therapeutics Holdings (ARCT) Retained Earnings (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings' Retained Earnings history runs 9 years deep, the most recent figure standing at -$541.6 million for Q1 2026.
- Quarterly Retained Earnings fell 17.0% year-over-year to -$541.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$541.6 million (down 17.0% YoY) and the FY2025 annual result came in at -$514.6 million, down 174.6% from the prior year.
- Retained Earnings was -$541.6 million for Q1 2026 at Arcturus Therapeutics Holdings, down from -$514.6 million in the prior quarter.
- Across five years, Retained Earnings topped out at $710.0 million in Q3 2025 and bottomed at -$541.6 million in Q1 2026.
- A 5-year average of -$281.2 million and a median of -$398.7 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings surged 287.49% — and 2025, when it tumbled 174.6%.
- Arcturus Therapeutics Holdings' Retained Earnings stood at -$338.1 million in 2022, then retreated by 8.8% to -$367.9 million in 2023, then jumped by 287.49% to $689.8 million in 2024, then tumbled by 174.6% to -$514.6 million in 2025, then declined by 5.24% to -$541.6 million in 2026.
- Business Quant data shows ARCT's Retained Earnings at -$541.6 million in Q1 2026, -$514.6 million in Q4 2025, and $710.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Arcturus Therapeutics Holdings | 164.57 Mn | -46.81 Mn | - | -541.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -541.55 Mn |
| Dec 31, 2025 | -514.59 Mn |
| Sep 30, 2025 | 710.04 Mn |
| Jun 30, 2025 | -472.06 Mn |
| Mar 31, 2025 | -462.88 Mn |
| Dec 31, 2024 | 689.76 Mn |
| Sep 30, 2024 | -418.80 Mn |
| Jun 30, 2024 | -411.90 Mn |
| Mar 31, 2024 | -394.70 Mn |
| Dec 31, 2023 | -367.90 Mn |
| Sep 30, 2023 | -356.16 Mn |
| Jun 30, 2023 | -339.94 Mn |
| Mar 31, 2023 | -287.40 Mn |
| Dec 31, 2022 | -338.14 Mn |
| Sep 30, 2022 | -455.49 Mn |
| Jun 30, 2022 | -420.22 Mn |
| Mar 31, 2022 | -398.70 Mn |
| Dec 31, 2021 | 575.68 Mn |
| Sep 30, 2021 | -308.83 Mn |
| Jun 30, 2021 | -254.74 Mn |